One of the biotech stocks highlighted in today’s article is a well-established, large-cap name. The other is a far less established, small-cap player with no products currently on the market. What the two have in common, according to the author, is that both “have made significant breakthroughs — and could provide market-beating returns for many years to come as a result.” For these two biotech stocks to consider – one that currently dominates the cystic fibrosis market and one that is likely to disrupt the diabetes market – CLICK HERE.
Bad News For Its Competitor Could Be Great News For This Small-Cap Biotech – And Its Shareholders
In January, the small-cap biotech highlighted in today’s article received FDA approval for its treatment for childhood peanut allergy – and with peanut allergy being the most common food allergy in the U.S. (with cases of the condition rising rapidly) and the fact that this is currently the only FDA-approved treatment for the condition (thanks to a competitor encountering some regulatory roadblocks), this drug has the potential to become a blockbuster product. For more, CLICK HERE.
ETFs: A Remedy For Biotech Risks
The solution to the substantial risks associated with biotech stocks (especially small biotech firms)? Biotech ETFs! Today’s article highlights six biotech ETFs to consider buying, noting that “Some provide well-rounded access to the space, while others acutely focus on certain aspects of the space, such as cancer treatments or drugs to battle infectious diseases.” For these six biotech ETFs, CLICK HERE.
A Look At One Of The Newest COVID-19 Stocks
Joining the ever-expanding list of COVID-19 stocks is this biotech that has filed an application with the FDA for initiation of Phase 2/Phase 3 clinical trials for its experimental monoclonal antibody therapy for the disease. The safety and tolerability of the therapy has already been demonstrated and, as today’s article explains, the company believes that its modulating effect “could reduce the number of ICU patients and decrease the need for mechanical ventilation, ultimately saving lives.” For more, CLICK HERE.
This Little-Known Biotech’s Blood Plasma-Based Coronavirus Therapy Could Soon Bring It A Lot Of Attention
Of all the companies working on the development of potential COVID-19 vaccines and therapeutics, the one highlighted in today’s article – a small Israel-based biotech that specializes in blood plasma-based treatments – is one of the least well-known. However, given that plasma-based therapies have already been shown to be effective in treating severe cases of COVID-19, this company could start getting a lot more attention as its coronavirus therapy moves on to further clinical testing – and that could send its stock soaring. So is this stock a smart buy? CLICK HERE.
4 Biotech Penny Stocks To Watch For COVID And Non-COVID Reasons
Noting that “biotechnology and healthcare penny stocks are making waves in the market”, the author of today’s article highlights four biotech penny stocks to watch that have been gaining attention this year, both for developments related to the COVID-19 crisis and developments unrelated to the COVID-19 crisis. For these four biotech penny stocks to watch, CLICK HERE.
Reading The Penny Stock News
“While large-cap stocks might spike slightly on certain headlines, more times than not, penny stocks tend to experience a compound effect,” notes the author of today’s article, who proceeds to examine three penny stocks that have recently had big news – and what that news could mean for those stocks heading into the final week of July. For more, CLICK HERE.
“Already Lucrative And Growing Like Gangbusters”: The Little-Known Biotech Segment Set For A Massive Breakout
“As an investor, this sets up a great opportunity to get in on the ground floor and earn triple-digit profits in short order,” advises the author of today’s article in regards to a little-known segment of the thriving biotech industry that appears poised for a massive breakout to the upside in the coming months. Just what is this biotech segment that’s deserving of attention? CLICK HERE.
The End Of The TINA Trade?
Are we approaching the end of the TINA – “There Is No Alternative” (to buying stocks) – trade? The author of today’s article believes that’s likely the case, stating that “U.S. stocks are trading at a historically high premium… And in the coming weeks, stocks are about to get a lot more expensive. This, coupled with the realities associated with the economic outlook, have important implications for the U.S. stock market outlook.” For more, CLICK HERE.
The Future Of CRISPR
Given the fact that it has already demonstrated remarkable performance without even having any products with regulatory approval for sale, just where could biotech CRISPR Therapeutics, with its focus on the treatment of serious diseases using its proprietary CRISPR/Cas9 gene-editing platform, be five years from now? For more on the promise of this firm’s pipeline projects, CLICK HERE.
